Drug
Adx 629
Adx 629: highest development phase Phase 2, developed by Aldeyra Therapeutics, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Aldeyra Therapeutics, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| ADX-629 (Open-label) NCT05717920 | Phase 2 | Atopic Dermatitis |
Latest
No recent events.
Follow Adx 629 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.